Pertussis vaccines and the challenge of inducing durable immunity

Current Opinion in Immunology

Volumn 35, Issue , 2015, Pages 48-54

  Warfel, Jason M ^a   Edwards, Kathryn M ^b,c  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMAGGLUTININ; PERTACTIN; PERTUSSIS VACCINE; ACELLULAR VACCINE;

ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; B LYMPHOCYTE; BABOON; BACTERIAL STRAIN; BACTERIUM ISOLATION; CELL EXPANSION; CELLULAR IMMUNITY; DISEASE PREDISPOSITION; DISEASE TRANSMISSION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; MEMORY CELL; NONHUMAN; PERTUSSIS; PROTEIN EXPRESSION; PROTEIN PURIFICATION; REVIEW; TH1 CELL; TH17 CELL; TH2 CELL; VACCINATION; ANIMAL; IMMUNITY; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; WHOOPING COUGH;

ANIMALS; B-LYMPHOCYTES; HUMANS; IMMUNITY; IMMUNOLOGIC MEMORY; PERTUSSIS VACCINE; TH1 CELLS; TH17 CELLS; TH2 CELLS; VACCINATION; VACCINES, ACELLULAR; WHOOPING COUGH;

EID: 84936166523     PISSN: 09527915     EISSN: 18790372     Source Type: Journal    
DOI: 10.1016/j.coi.2015.05.008     Document Type: Review

References (64)

1. Melvin J.A., Scheller E.V., Miller J.F., Cotter P.A. Bordetella pertussis pathogenesis: current and future challenges. Nat Rev Microbiol 2014, 12:274-288.
2. Mattoo S., Cherry J.D. Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies. Clin Microbiol Rev 2005, 18:326-382.
3. Clark T.A. Changing pertussis epidemiology: everything old is new again. J Infect Dis 2014, 209:978-981.
4. Cody C.L., Baraff L.J., Cherry J.D., Marcy S.M., Manclark C.R. Nature and rates of adverse reactions associated with DTP and DT immunizations in infants and children. Pediatrics 1981, 68:650-660.
5. Edwards K.M., Meade B.D., Decker M.D., Reed G.F., Rennels M.B., Steinhoff M.C., Anderson E.L., Englund J.A., Pichichero M.E., Deloria M.A. Comparison of 13 acellular pertussis vaccines: overview and serologic response. Pediatrics 1995, 96:548-557.
6. Greco D., Salmaso S., Mastrantonio P., Giuliano M., Tozzi A.E., Anemona A., Ciofi degli Atti M.L., Giammanco A., Panei P., Blackwelder W.C., et al. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group. N Engl J Med 1996, 334:341-348.
7. Gustafsson L., Hallander H.O., Olin P., Reizenstein E., Storsaeter J. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N Engl J Med 1996, 334:349-355.
8. Stehr K., Cherry J.D., Heininger U., Schmitt-Grohé S., uberall M., Laussucq S., Eckhardt T., Meyer M., Engelhardt R., Christenson P. A comparative efficacy trial in Germany in infants who received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP vaccine, or DT vaccine. Pediatrics 1998, 101:1-11.
9. Simondon F., Preziosi M.P., Yam A., Kane C.T., Chabirand L., Iteman I., Sanden G., Mboup S., Hoffenbach A., Knudsen K., et al. A randomized double-blind trial comparing a two-component acellular to a whole-cell pertussis vaccine in Senegal. Vaccine 1997, 15:1606-1612.
10. CDC Notifiable diseases and mortality tables. Morb Mortal Wkly Rep 2013, 62:669-682.
11. Lugauer S., Heininger U., Cherry J.D., Stehr K. Long-term clinical effectiveness of an acellular pertussis component vaccine and a whole cell pertussis component vaccine. Eur J Pediatr 2002, 161:142-146.
12. Salmaso S., Mastrantonio P., Tozzi A.E., Stefanelli P., Anemona A., Ciofi degli Atti M.L., Giammanco A., Group S.I.W. Sustained efficacy during the first 6 years of life of 3-component acellular pertussis vaccines administered in infancy: the Italian experience. Pediatrics 2001, 108:E81.
13. Taranger J., Trollfors B., Lagergård T., Lind L., Sundh V., Zackrisson G., Bryla D.A., Robbins J.B. Unchanged efficacy of a pertussis toxoid vaccine throughout the two years after the third vaccination of infants. Pediatr Infect Dis J 1997, 16:180-184.
14. Winter K., Glaser C., Watt J., Harriman K., CDC Pertussis epidemic-California, 2014. MMWR Morb Mortal Wkly Rep 2014, 63:1129-1132.
15. Winter K., Harriman K., Zipprich J., Schechter R., Talarico J., Watt J., Chavez G. California pertussis epidemic, 2010. J Pediatr 2012, 161:1091-1096.
16. CDC Pertussis epidemic-Washington, 2012. Morb Mortal Wkly Rep 2012, 61:517-522.
17. CDC Pertussis vaccination: use of acellular pertussis vaccines among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1997, 46:1-25.
18. Libster R., Edwards K.M. Re-emergence of pertussis: what are the solutions?. Expert Rev Vaccines 2012, 11:1331-1346.
19. Misegades L.K., Winter K., Harriman K., Talarico J., Messonnier N.E., Clark T.A., Martin S.W. Association of childhood pertussis with receipt of 5 doses of pertussis vaccine by time since last vaccine dose, California, 2010. JAMA 2012, 308:2126-2132.
20. Klein N.P., Bartlett J., Rowhani-Rahbar A., Fireman B., Baxter R. Waning protection after fifth dose of acellular pertussis vaccine in children. N Engl J Med 2012, 367:1012-1019.
21. Tartof S.Y., Lewis M., Kenyon C., White K., Osborn A., Liko J., Zell E., Martin S., Messonnier N.E., Clark T.A., et al. Waning immunity to pertussis following 5 doses of DTaP. Pediatrics 2013, 131:e1047-e1052.
22. Witt M.A., Katz P.H., Witt D.J. Unexpectedly limited durability of immunity following acellular pertussis vaccination in preadolescents in a North American outbreak. Clin Infect Dis 2012, 54:1730-1735.
23. McGirr A., Fisman D.N. Duration of pertussis immunity after DTaP immunization: a meta-analysis. Pediatrics 2015, 135:331-343.
24. Koepke R., Eickhoff J.C., Ayele R.A., Petit A.B., Schauer S.L., Hopfensperger D.J., Conway J.H., Davis J.P. Estimating the effectiveness of tetanus-diphtheria-acellular pertussis vaccine (Tdap) for preventing pertussis: evidence of rapidly waning immunity and difference in effectiveness by Tdap brand. J Infect Dis 2014, 210:942-953.
25. Bart M.J., Harris S.R., Advani A., Arakawa Y., Bottero D., Bouchez V., Cassiday P.K., Chiang C.S., Dalby T., Fry N.K., et al. Global population structure and evolution of Bordetella pertussis and their relationship with vaccination. MBio 2014, 5.
26. Pawloski L.C., Queenan A.M., Cassiday P.K., Lynch A.S., Harrison M.J., Shang W., Williams M.M., Bowden K.E., Burgos-Rivera B., Qin X., et al. Prevalence and molecular characterization of pertactin-deficient Bordetella pertussis in the United States. Clin Vaccine Immunol 2014, 21:119-125.
27. Queenan A.M., Cassiday P.K., Evangelista A. Pertactin-negative variants of Bordetella pertussis in the United States. N Engl J Med 2013, 368:583-584.
28. Hegerle N., Guiso N. Bordetella pertussis and pertactin-deficient clinical isolates: lessons for pertussis vaccines. Expert Rev Vaccines 2014, 13:1135-1146.
29. Lam C., Octavia S., Ricafort L., Sintchenko V., Gilbert G.L., Wood N., McIntyre P., Marshall H., Guiso N., Keil A.D., et al. Rapid increase in pertactin-deficient Bordetella pertussis isolates, Australia. Emerg Infect Dis 2014, 20:626-633.
30. Martin S.W., Pawloski L., Williams M., Weening K., DeBolt C., Qin X., Reynolds L., Kenyon C., Giambrone G., Kudish K., et al. Pertactin-negative Bordetella pertussis strains: evidence for a possible selective advantage. Clin Infect Dis 2015, 60:223-227.
31. Witt M.A., Arias L., Katz P.H., Truong E.T., Witt D.J. Reduced risk of pertussis among persons ever vaccinated with whole cell pertussis vaccine compared to recipients of acellular pertussis vaccines in a large US cohort. Clin Infect Dis 2013, 56:1248-1254.
32. Liko J., Robison S.G., Cieslak P.R. Priming with whole-cell versus acellular pertussis vaccine. N Engl J Med 2013, 368:581-582.
33. Sheridan S.L., Ware R.S., Grimwood K., Lambert S.B. Number and order of whole cell pertussis vaccines in infancy and disease protection. JAMA 2012, 308:454-456.
34. Klein N.P., Bartlett J., Fireman B., Rowhani-Rahbar A., Baxter R. Comparative effectiveness of acellular versus whole-cell pertussis vaccines in teenagers. Pediatrics 2013, 131:e1716-e1722.
35. Edwards K.M. Review of the laboratory approaches to the detection of antibody and cell-mediated immunity to pertussis disease and vaccine. Expert Rev Vaccines 2014, 13:1183-1190.
36. Amanna I.J., Carlson N.E., Slifka M.K. Duration of humoral immunity to common viral and vaccine antigens. N Engl J Med 2007, 357:1903-1915.
37. Le T., Cherry J.D., Chang S.J., Knoll M.D., Lee M.L., Barenkamp S., Bernstein D., Edelman R., Edwards K.M., Greenberg D., et al. Immune responses and antibody decay after immunization of adolescents and adults with an acellular pertussis vaccine: the APERT study. J Infect Dis 2004, 190:535-544.
38. Berbers G.A., van de Wetering M.S., van Gageldonk P.G., Schellekens J.F., Versteegh F.G., Teunis P.F. A novel method for evaluating natural and vaccine induced serological responses to Bordetella pertussis antigens. Vaccine 2013, 31:3732-3738.
39. Dalby T., Petersen J.W., Harboe Z.B., Krogfelt K.A. Antibody responses to pertussis toxin display different kinetics after clinical Bordetella pertussis infection than after vaccination with an acellular pertussis vaccine. J Med Microbiol 2010, 59:1029-1036.
40. Slifka M.K., Amanna I. How advances in immunology provide insight into improving vaccine efficacy. Vaccine 2014, 32:2948-2957.
41. Schure R.M., Hendrikx L.H., de Rond L.G., Oztürk K., Sanders E.A., Berbers G.A., Buisman A.M. Differential T- and B-cell responses to pertussis in acellular vaccine-primed versus whole-cell vaccine-primed children 2 years after preschool acellular booster vaccination. Clin Vaccine Immunol 2013, 20:1388-1395.
42. Hendrikx L.H., de Rond L.G., Oztürk K., Veenhoven R.H., Sanders E.A., Berbers G.A., Buisman A.M. Impact of infant and preschool pertussis vaccinations on memory B-cell responses in children at 4 years of age. Vaccine 2011, 29:5725-5730.
43. Carollo M., Pandolfi E., Tozzi A.E., Buisman A.M., Mascart F., Ausiello C.M. Humoral and B-cell memory responses in children five years after pertussis acellular vaccine priming. Vaccine 2014, 32:2093-2099.
44. Stenger R.M., Smits M., Kuipers B., van Gaans-van den Brink J., Poelen M., Boog C.J., van Els C.A. Impaired long-term maintenance and function of Bordetella pertussis specific B cell memory. Vaccine 2010, 28:6637-6646.
45. Baker J.D., Halperin S.A., Edwards K., Miller B., Decker M., Stephens D. Antibody response to Bordetella pertussis antigens after immunization with American and Canadian whole-cell vaccines. J Pediatr 1992, 121:523-527.
46. Higgs R., Higgins S.C., Ross P.J., Mills K.H. Immunity to the respiratory pathogen Bordetella pertussis. Mucosal Immunol 2012, 5:485-500.
47. Vermeulen F., Dirix V., Verscheure V., Damis E., Vermeylen D., Locht C., Mascart F. Persistence at one year of age of antigen-induced cellular immune responses in preterm infants vaccinated against whooping cough: comparison of three different vaccines and effect of a booster dose. Vaccine 2013, 31:1981-1986.
48. Edwards K.M., Berbers G.A. Immune responses to pertussis vaccines and disease. J Infect Dis 2014, 209(Suppl. 1):S10-S15.
49. Dirix V., Verscheure V., Goetghebuer T., Hainaut M., Debrie A.S., Locht C., Mascart F. Cytokine and antibody profiles in 1-year-old children vaccinated with either acellular or whole-cell pertussis vaccine during infancy. Vaccine 2009, 27:6042-6047.
50. Mascart F., Verscheure V., Malfroot A., Hainaut M., Piérard D., Temerman S., Peltier A., Debrie A.S., Levy J., Del Giudice G., et al. Bordetella pertussis infection in 2-month-old infants promotes type 1 T cell responses. J Immunol 2003, 170:1504-1509.
51. Smits K., Pottier G., Smet J., Dirix V., Vermeulen F., De Schutter I., Carollo M., Locht C., Ausiello C.M., Mascart F. Different T cell memory in preadolescents after whole-cell or acellular pertussis vaccination. Vaccine 2013, 32:111-118.
52. Ross P.J., Sutton C.E., Higgins S., Allen A.C., Walsh K., Misiak A., Lavelle E.C., McLoughlin R.M., Mills K.H. Relative contribution of Th1 and Th17 cells in adaptive immunity to Bordetella pertussis: towards the rational design of an improved acellular pertussis vaccine. PLoS Pathog 2013, 9:e1003264.
53. Kolls J.K., Khader S.A. The role of Th17 cytokines in primary mucosal immunity. Cytokine Growth Factor Rev 2010, 21:443-448.
54. Schure R.M., Hendrikx L.H., de Rond L.G., Oztürk K., Sanders E.A., Berbers G.A., Buisman A.M. T-cell responses before and after the fifth consecutive acellular pertussis vaccination in 4-year-old Dutch children. Clin Vaccine Immunol 2012, 19:1879-1886.
55. Warfel J.M., Merkel T.J. The baboon model of pertussis: effective use and lessons for pertussis vaccines. Expert Rev Vaccines 2014, 13:1241-1252.
56. Warfel J.M., Beren J., Merkel T.J. Airborne transmission of Bordetella pertussis. J Infect Dis 2012, 206:902-906.
57. Warfel J.M., Beren J., Kelly V.K., Lee G., Merkel T.J. Nonhuman primate model of pertussis. Infect Immun 2012, 80:1530-1536.
58. Warfel J.M., Zimmerman L.I., Merkel T.J. Acellular pertussis vaccines protect against disease but fail to prevent infection and transmission in a nonhuman primate model. Proc Natl Acad Sci U S A 2014, 111:787-792.
59. Warfel J.M., Merkel T.J. Bordetella pertussis infection induces a mucosal IL-17 response and long-lived Th17 and Th1 immune memory cells in nonhuman primates. Mucosal Immunol 2013, 6:787-796.
60. CDC Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) in pregnant women-Advisory Committee on Immunization Practices (ACIP), 2012. Morb Mortal Wkly Rep 2013, 62:131-135.
61. Munoz F.M., Bond N.H., Maccato M., Pinell P., Hammill H.A., Swamy G.K., Walter E.B., Jackson L.A., Englund J.A., Edwards M.S., et al. Safety and immunogenicity of tetanus, diphtheria and acellular pertussis (Tdap) immunization during pregnancy in mothers and infants: a randomized clinical trial. JAMA 2014, 311:1760-1769.
62. Amirthalingam G., Andrews N., Campbell H., Ribeiro S., Kara E., Donegan K., Fry N.K., Miller E., Ramsay M. Effectiveness of maternal pertussis vaccination in England: an observational study. Lancet 2014, 384:1521-1528.
63. Meade B.D., Plotkin S.A., Locht C. Possible options for new pertussis vaccines. J Infect Dis 2014, 209(Suppl. 1):S24-S27.
64. Merkel T.J., Halperin S.A. Nonhuman primate and human challenge models of pertussis. J Infect Dis 2014, 209(Suppl. 1):S20-S23.